Head of Commercial Operations, Arctoris
BIOGRAPHY
Advancing Neuroinflammation Research with iPSC-Derived Microglia and Automated Assays for Drug Discovery
Speakers
-
Travis Hardcastle
Senior Product Manager, Engineered Cells, EditCo Bio.BIOGRAPHY -
Seth Hanson, M.S.
Business Development Manager, BrainxellBIOGRAPHY
Event Date & Time
Date: April 16, 2025
Time: 9:00am PDT, 12:00pm EDT
Abstract
Are current neuroinflammation models constraining your research? Traditional animal-derived cell assays lack the complexity of human microglia, limiting their predictive value and impeding progress in drug discovery for neurodegenerative diseases such as Alzheimer’s, Parkinson’s, and ALS. Despite these limitations, their scalability has historically been essential for high-throughput screening.
Join our webinar to explore how Brainxell, Editco, and Arctoris are leveraging CRISPR-edited, iPSC-derived human microglia in automated, multiplexed assays to enhance disease modeling and drug discovery. This approach integrates human-relevant cellular models with mid-throughput automation and comprehensive neuroinflammatory readouts including phagocytosis, cytokine response, and inflammasome modulation.
Key Benefits:
- Enhanced Predictive Power – Improve translational relevance with physiologically representative human microglia models.
- Increased Efficiency – Miniaturized, multiplexed assays enable high-content screening and mechanistic insights while optimizing time and resources.
- Scalable, Reproducible Workflows – A modular, automated platform ensures robust, consistent data for improved decision-making in drug development.
If you are developing therapeutics targeting microglial function and require translatable, scalable assay solutions to accelerate your pipeline, this webinar will provide essential insights. Unlock the Future of Neuroinflammation Research – Register Now!
Webinars will be available for unlimited on-demand viewing after live event.
Loading Comments...